Salvage surgery after definitive chemo-radiotherapy for patients with Non-Small Cell Lung Cancer

• Published in: Lung cancer (Amsterdam, Netherlands) Netherlands), 2019-07, Vol.133, p.117-122
• Main Authors: Romero-Vielva, Laura, Viteri, Santiago, Moya-Horno, Irene, Toscas, José Ignacio, Maestre-Alcácer, José Antonio, Ramón y Cajal, Santiago, Rosell, Rafael
• Format: Article
• Language: English
• Subjects: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Carcinoma, Non-Small-Cell Lung - mortality; Carcinoma, Non-Small-Cell Lung - surgery; Carcinoma, Non-Small-Cell Lung - therapy; Chemoradiotherapy - methods; Definitive chemoradiotherapy; Female; Humans; Lung cancer; Lung Neoplasms - mortality; Lung Neoplasms - surgery; Lung Neoplasms - therapy; Male; Middle Aged; Neoplasm Staging; Non-small cell lung cancer; Pneumonectomy - methods; Retrospective Studies; Salvage surgery; Salvage Therapy - methods; Survival Analysis
• ISSN: 0169-5002; 1872-8332
• DOI: 10.1016/j.lungcan.2019.05.010

•Surgery after definitive chemoradiotherapy in lung cancer is technically feasible.•Morbidity and mortality were low due to a thoughtful selection of patients.•A 5-year survival of 53.3% was comparable to the published previously.•Salvage surgery in lung cancer patients can achieve good long-term outcomes. Despite all treatment advances, lung cancer is still the main cause of death worldwide. Treatment for resectable stage IIIA remains controversial including definitive chemoradiotherapy and induction treatment followed by surgery. After definitive chemoradiation up to 35% of patients will relapse locally. Experience with salvage resection after definitive chemoradiotherapy in lung cancer is limited. We present our experience in 27 patients who underwent surgical resection after definitive treatment. Between January 2007 and December 2016, 27 patients were evaluated in our department for surgical resection after receiving definitive chemoradiation treatment in different institutions. We conducted a retrospective study gathering the following data: age, gender, clinical and pathologic stage, histology, chemotherapy treatment regimen, radiotherapy dosage, surgical procedure and complications. Time between surgical resection and last follow-up was used to calculate Overall Survival (OS). Disease-Free Survival (DFS) was calculated from surgical resection to diagnosis of relapse. Most of the patients were men with a median age of 56.09 years. Median follow-up time was 46.94 months. All patients received platinum-based chemotherapy regimen and high-dose radiotherapy, except for one patient who received 45 Gy. Lobectomy and bilobectomy was performed in 7 patients each, and pneumonectomy in 13. Complications appeared in 5 patients. Bronchopleural fistula appeared in two patients, and only one death in the early postoperative period. The analysis showed an OS of 75.56 months, with 1-year, 3-year and 5-year survival of 74.1%, 57.8% and 53.3% respectively. Salvage surgery in selected patients is technically feasible, with low morbidity and mortality rates and good long-term outcomes.